Shares of China Biologic Products (NASDAQ:CBPO) have been assigned an average recommendation of “Hold” from the seven brokerages that are currently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, two have given a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $101.00.
Several research analysts have weighed in on the stock. ValuEngine cut shares of China Biologic Products from a “hold” rating to a “sell” rating in a report on Saturday. BidaskClub raised shares of China Biologic Products from a “sell” rating to a “hold” rating in a report on Saturday, April 7th. Jefferies Group reissued a “buy” rating and issued a $97.00 price target on shares of China Biologic Products in a report on Thursday, March 15th. Zacks Investment Research cut shares of China Biologic Products from a “hold” rating to a “sell” rating in a report on Monday, March 5th. Finally, TheStreet cut shares of China Biologic Products from a “b-” rating to a “c+” rating in a report on Thursday, March 1st.
Shares of CBPO stock opened at $85.73 on Friday. The stock has a market capitalization of $2,915.69, a PE ratio of 17.32, a PEG ratio of 1.34 and a beta of 1.46. China Biologic Products has a 52-week low of $71.85 and a 52-week high of $120.46.
China Biologic Products (NASDAQ:CBPO) last issued its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.90 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.89 by $0.01. The company had revenue of $90.10 million for the quarter, compared to analysts’ expectations of $85.15 million. China Biologic Products had a net margin of 18.34% and a return on equity of 21.30%. China Biologic Products’s quarterly revenue was up 16.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.95 EPS. analysts predict that China Biologic Products will post 5.22 earnings per share for the current year.
A number of institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC raised its holdings in China Biologic Products by 42.7% in the 4th quarter. Millennium Management LLC now owns 33,176 shares of the biopharmaceutical company’s stock valued at $2,613,000 after acquiring an additional 9,932 shares during the period. Two Sigma Investments LP raised its holdings in China Biologic Products by 124.9% in the 4th quarter. Two Sigma Investments LP now owns 44,704 shares of the biopharmaceutical company’s stock valued at $3,521,000 after acquiring an additional 24,826 shares during the period. York Capital Management Global Advisors LLC raised its holdings in China Biologic Products by 430.9% in the 4th quarter. York Capital Management Global Advisors LLC now owns 160,847 shares of the biopharmaceutical company’s stock valued at $12,670,000 after acquiring an additional 130,549 shares during the period. Goldman Sachs Group Inc. raised its holdings in China Biologic Products by 854.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 597,399 shares of the biopharmaceutical company’s stock valued at $47,057,000 after acquiring an additional 534,824 shares during the period. Finally, Rudman Errol M raised its holdings in China Biologic Products by 6.7% in the 4th quarter. Rudman Errol M now owns 28,701 shares of the biopharmaceutical company’s stock valued at $2,261,000 after acquiring an additional 1,800 shares during the period. 58.65% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: “China Biologic Products (CBPO) Given Average Rating of “Hold” by Brokerages” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/21/china-biologic-products-cbpo-given-average-rating-of-hold-by-brokerages.html.
China Biologic Products Company Profile
China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.
Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.